CAMBRIDGE, Mass., Feb. 25, 2016 /PRNewswire/ -- Metamark Genetics, Inc., ("Metamark" or the "Company"), a leader in commercializing high-value urologic oncology products, today announced that Jerry Williamson has been named as the Company's new President, Chief Executive Officer, and Director. Mr. Williamson succeeds Ken Weg, who will retain an active role as Chairman of Metamark's Board of Directors.
Metamark's independent lead director of the Board of Directors, Gregory C. Critchfield, M.D., said,
"We are delighted to have Jerry Williamson step into this principal role at a time when commercial growth is paramount to the Company. Jerry's accomplished career spans more than 25 years of success within diagnostics and life sciences. Under Jerry's leadership, we anticipate a very bright future for Metamark, for its investors, and especially for patients, as we expand and commercialize Metamark's highly innovative clinical testing services." Dr. Critchfield added, "We express our sincere thanks to Ken Weg for his recent outstanding contributions to Metamark. We are very pleased to have Ken continue to impart his expert guidance and wisdom in his role as Co-founder and Chairman of Metamark's Board of Directors."
"Every day Metamark provides critical information for the identification, diagnosis, prognosis, and most effective treatment of urological cancer," stated Mr. Williamson. "Metamark's growing array of innovative testing helps prostate cancer patients and their physicians during the entire diagnostic and therapeutic care journey. ProMark®, our lead prognostic product, and Progensa® PCA3, an advanced urine-based molecular diagnostic product, together enable our overarching mission: to achieve improved outcomes through the availability of better information. I am incredibly excited about leading Metamark in its continued growth."
Mr. Williamson joined Metamark in 2015 as Chief Commercial Officer, bringing significant commercial operating and business development experience to the Company. In his career, he has held executive leadership roles responsible for value creation, growth, and profitability. Prior to Metamark, Mr. Williamson was a Partner with Flagship Ventures focused on building and developing relationships with corporate partners for the firm's core innovation and investment activities. He served as Vice President and General Manager for Molecular Devices, a Danaher operating company, with the responsibility of expanding growth in Emerging Markets. Mr. Williamson was President of Global Commercial Operations for Genetix Ltd., a UK-based diagnostic imaging company, and served as President of Biacore, Inc., where he was also responsible for post-acquisition integration into GE Healthcare. Mr. Williamson received a BS in Biochemistry from the University of Vermont and holds an MBA from Boston University.
Launched in late 2014, ProMark® is the first proteomic classifier of biopsied prostate tissue to assess whether an early-stage prostate tumor is aggressive or indolent. Test results generated in Metamark's Cambridge, Mass. CLIA-certified laboratory can aid the decision whether to treat the cancer aggressively or to choose a course of active surveillance.
About Progensa® PCA3
The Progensa® PCA3 assay from Hologic measures the concentration of prostate cancer gene 3 (PCA3) and prostate-specific antigen (PSA) RNA molecules in post-digital rectal exam (DRE) male urine specimens. The resulting PCA3 score predicts the results of repeat biopsies more accurately than traditional serum PSA testing in men who have had one or more previous negative prostate biopsies. When used with other patient information, the Progensa® PCA3 assay may help address some challenges urologists face with identifying prostate cancers, while reducing unnecessary repeat biopsies.
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.
For more information, please visit the company's website: www.metamarkgenetics.com.
Metamark® and ProMark® are registered trademarks of Metamark Genetics, Inc.
Progensa® is a registered trademark of Hologic, Inc.
SOURCE Metamark Genetics, Inc.